Filing Details

Accession Number:
0001209191-19-009630
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-02-13 16:27:54
Reporting Period:
2019-02-11
Accepted Time:
2019-02-13 16:27:54
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
875320 Vertex Pharmaceuticals Inc / Ma VRTX Pharmaceutical Preparations (2834) 043039129
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1446372 M Paul Silva C/O Vertex Pharmaceuticals Incorporated
50 Northern Avenue
Boston MA 02210
Svp & Interim Cfo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2019-02-11 1,400 $179.35 23,386 No 4 S Direct
Common Stock Disposition 2019-02-11 2,100 $180.38 21,286 No 4 S Direct
Common Stock Disposition 2019-02-11 715 $181.09 20,571 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 169 Indirect 401(k)
Footnotes
  1. Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1.
  2. Open market sales reported on this line occurred at a weighted average price of $179.35 (range $178.75 to $179.64).
  3. Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
  4. Open market sales reported on this line occurred at a weighted average price of $180.38 (range $179.78 to $180.76).
  5. Open market sales reported on this line occurred at a weighted average price of $181.09 (range $180.88 to $181.36).